<br>PROFESSOR JAN WADSTEIN
'Zymbilan® takes the guesswork out of recommending and choosing an effective skincare therapy for dry itchy and scaly skin – such as Psoriasis and Dermatitis etc. As medical professionals, we recognise that real therapeutic treatment of chronic skin care conditions such as psoriasis happens only by stimulating, supporting, and strengthening the normal skin rebuilding process. The Zymbilan® Dual Action Therapy for psoriatic skin is based on more than three decades of targeted research, and it delivers real objective measurable results.'


PROFESSOR JAN WADSTEIN

MD, PhD, Associate Professor at Lund University, Member of the Royal Society of Medicine

With a career spanning over 40 years and more than 100 publications, Dr. Wadstein is a respected researcher and professor in the field of medicine. He has been a director at Bayer, among others, and worked as a medical officer for Boots UK. Dr. Wadstein has held many leading professorships throughout his career, as well as several honorary professorships globally.
<br>DR ERLING THOM
'Zymbilan® is probably the most effective documented symptom relief programme in the world, when it comes to addressing Psoriasis and other dry scaly skin conditions. As a part of my extensive clinical research, I have been able to demonstrate scientifically objective results that Zymbilan® has a highly significant favourable effect on skin quality and expression compared to placebo in subjects with mild to moderate psoriasis.'


DR ERLING THOM

PhD Pharmacology, Stanford University

With over 30 years of expertise in clinical trial management and clinical development, Dr. Thom is an independent researcher with extensive experience in the areas of cardiology, rheumatology, neurology, dermatology, nutrition, and several pharmacokinetic studies. Dr. Thom has been a director at Ciba-Geigy, and for many years has been a director at Parexel. With over 15,000 employees operating in more than 50 countries, Parexel is one of the world’s largest comprehensive drug development and contract research organisations.